Julius Fink,Shigeo Horie
Julius Fink
Introduction: Testosterone replacement therapy is a promising and growing field in modern healthcare. Several novel testosterone preparations aiming at providing an efficient drug without side effects have been developed ...
An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program [0.03%]
tirzepatide治疗2型糖尿病最新研究进展：三期临床试验成果汇总聚焦
Juan Pablo Frías
Juan Pablo Frías
Introduction: Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), received regulatory approval from the U.S. Food and Drug Administration...
Arup Kumar Misra,Gaurav Rangari,Madhavrao C et al.
Arup Kumar Misra et al.
Introduction: Diabetes mellitus (DM) and the 2019 coronavirus (COVID-19) appear to interact in both directions. There is mounting proof that patients with DM have a worse COVID-19 prognosis than those without it. Pharmaco...
Significant publications in diabetes pharmacotherapy and technology in 2020 [0.03%]
2020年糖尿病药物治疗及技术领域重要文献回顾
Jennifer N Clements,Rachel Franks,Diana Isaacs et al.
Jennifer N Clements et al.
Introduction: The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are ...
Arup Kumar Misra,Gaurav Rangari,Madhavrao C et al.
Arup Kumar Misra et al.
Introduction: Diabetes mellitus (DM) and the 2019 coronavirus (COVID-19) appear to interact in both directions. There is mounting proof that patients with DM have a worse COVID-19 prognosis than those without it. Pharmaco...
Stephen James Smith,Adrian Leo Lopresti,Timothy John Fairchild
Stephen James Smith
Introduction: Testosterone concentrations in men decline with advancing age, with low testosterone concentrations being associated with multiple morbidities, an increased risk of early mortality, and a reduced quality of ...
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series [0.03%]
替莫唑胺治疗反应性的侵袭性垂体肿瘤和癌的停药时机：系统评价及帕多瓦（意大利）病例系列
Marta Padovan,Giulia Cerretti,Mario Caccese et al.
Marta Padovan et al.
Introduction: Pituitary adenomas can show a tendency to grow, despite multimodal treatment. Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors. TMZ requires a careful balanc...
HDACs as an emerging target in endocrine tumors: a comprehensive review [0.03%]
组蛋白去乙酰化酶在内分泌肿瘤中的新兴作用及其研究进展：综述文章
Eckhard Klieser,Bettina Neumayer,Pietro Di Fazio et al.
Eckhard Klieser et al.
Introduction: The pathogenic role of deregulated histone (de-)acetylation by histone deacetyles (HDACs) has been demonstrated in several human cancers. While some HDAC inhibitors (HDACi) have been approved for individual ...